Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The general aim is to compare the effects of typical and atypical antipsychotic medication on brain structure and function. A parallel group treatment trial will be utilized to compare the effects of the typical antipsychotic thiothixene versus the atypical antipsychotics risperidone (RIS) and olanzapine (OLZ) on brain structure and function in schizophrenia in an effort to determine the neuroanatomic basis for cognitive pathology in schizophrenia and its amelioration by atypical antipsychotic drugs.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of North Carolina, Chapel Hill
• Treatments: Olanzapine; Risperidone; Thiothixene

Criteria

Inclusion Criteria:

Inclusion Criteria for Schizophrenia/Schizoaffective Subjects

1. Men and women between ages of 18 to 60 inclusive, of any ethnic origin.

2. Subjects must be right handed.

3. DSM IV criteria for chronic schizophrenia or schizoaffective disorder.

4. Good physical health as determined by complete physical examination, laboratory tests, and EKG

Inclusion Criteria for Healthy Control Subjects:

1. Fifteen individuals, matched to the patient subjects on the basis of age, gender, parental SES, handedness.

Exclusion Criteria:

Exclusion Criteria for Schizophrenia/Schizoaffective Subjects

1. Previous poor response or adverse side effects to thiothixene, olanzapine or risperidone.

2. Left handedness

3. Epilepsy, HIV, or current myeloproliferative disorder

4. Current severe major depression.

5. Current or past history of Substance Dependence (except caffeine or nicotine)

6. Criteria for active Substance Abuse within past 30 days

7. Learning disability

8. Mental Retardation

9. Foreign metal objects or implants as determined by MRI safety questionnaires

10. If judged unsuitable for the study based on other medical or psychiatric condition according to the PIs best clinical judgment.

11. No depot neuroleptic within 60 days before the day of randomization.

12. Women who are pregnant or breastfeeding, and/or unwilling to take a pregnancy test.

Exclusion Criteria for Healthy Control Subjects

1. History of psychiatric disorder or current medical illness